By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel consensus is that Grail's current valuation at 17x forward sales is overly optimistic given the uncertainty around FDA approval, Medicare coverage, and Galleri's clinical utility. The missed primary endpoint in the NHS trial and the potential low sensitivity of Galleri for early-stage cancers are significant concerns.
Risk: Low sensitivity of Galleri for early-stage cancers (16-20%)
Opportunity: None identified
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Grail (NASDAQ: GRAL), which was spun off from Illumina (NASDAQ: ILMN) in 2024, reached a record high of $116.06 on Jan. 22. But today, the cancer test developer's stock trades at just under $70. Is it a buy, sell, or hold at these levels?
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Grail's Galleri blood test aims to detect signals from dozens of cancers before any symptoms appear. That seems like a game changer for the oncology market, but its stock plunged in February after its largest NHS England trial failed to meet its primary endpoint. That trial was considered a crucial stepping stone toward an FDA approval in the U.S. -- which would clear the way for private insurance and Medicare plans to cover its tests.
However, Grail already sells Galleri on a cash-only basis (for $749 to $949) to independent customers, select employers, hospital pilots, and telehealth programs. Its NHS England trial also wasn't a complete failure: Galleri's users in the trial still had fewer Stage IV cancers detected, and it achieved earlier (Stage I and II) detection of the deadliest cancers.
Even without a near-term FDA approval, analysts expect Grail's revenue to grow from $147 million in 2025 to $281 million in 2028. It won't generate a profit anytime soon, and its stock isn't cheap at 17 times this year's sales, but an FDA approval could help it crush those estimates. Therefore, I think it's smarter to buy and hold Grail at under $70 than to hastily sell it.
Before you buy stock in Grail, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Grail wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $386,727! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,232,139!
Now, it’s worth noting Stock Advisor’s total average return is 906% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of August 1, 2026. *
Leo Sun has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Illumina. The Motley Fool recommends Grail. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"The NHS primary-endpoint miss materially delays or jeopardizes reimbursement, leaving Grail’s 17× sales multiple unsupported by current cash-pay traction."
The article frames Grail’s post-trial selloff as a buying opportunity at < $70, citing $147 M → $281 M revenue growth by 2028 and partial NHS positives. Yet the missed primary endpoint in the largest prospective trial materially raises the bar for FDA approval and Medicare coverage. At 17× 2025 sales with negative margins, the valuation assumes either rapid cash-pay adoption or eventual reimbursement that is now delayed and uncertain. Illumina spin-off also removed deep-pocketed parent support while competition in multi-cancer early detection intensifies. Missing context: Galleri’s real-world sensitivity for early-stage cancers remains ~16-20 % in independent studies, far below marketing claims.
If Galleri can scale cash-pay volume through employers and telehealth faster than expected, revenue could exceed consensus and the stock re-rates even without near-term FDA approval.
"Grail’s valuation relies on an optimistic regulatory path that ignores the significant clinical and reimbursement risks inherent in the post-NHS trial landscape."
Grail is currently a high-risk speculative play, not a fundamental value investment. Trading at 17x forward sales for a company without a clear path to profitability or FDA reimbursement is aggressive. The NHS trial failure isn't just a 'stepping stone' setback; it represents a massive hurdle for clinical validation and insurance coverage, which is the only way to scale beyond niche cash-pay customers. While the technology is revolutionary, the financial burn rate is unsustainable without a major catalyst. Investors are essentially betting on a binary regulatory outcome rather than organic growth. At $70, the market is pricing in a high probability of success that the current clinical data simply does not justify.
If Grail’s multi-cancer early detection (MCED) technology becomes the standard of care for high-risk populations, the addressable market is so vast that the current valuation could look like a bargain in hindsight.
"The NHS trial failure reveals clinical validation risk that the article minimizes, and 17x sales on speculative FDA approval and unproven cash-pay scaling is a bet on execution, not fundamentals."
Grail's valuation at 17x sales for a pre-profitability oncology company is aggressive even with 90% revenue CAGR through 2028. The NHS failure is being downplayed here—missing a primary endpoint in your flagship real-world trial is not a minor setback. It signals either that Galleri's clinical utility is narrower than marketed, or that detection alone (without mortality benefit) won't drive adoption. The $147M→$281M revenue forecast assumes cash-pay adoption accelerates and FDA approval materializes, but both are contingent on unproven demand. At $70, you're pricing in near-perfect execution with no margin for error.
Early-stage cancer detection is a massive TAM with zero competition; even modest cash-pay adoption ($750/test × millions of screening-age adults) could justify current valuation, and FDA approval remains possible despite the NHS setback if U.S. trial design is more favorable.
"Regulatory risk and uncertain payer reimbursement remain the dominant obstacles that could derail Grail's upside despite revenue growth."
Grail's NHS England miss adds a material regulatory risk that the FDA decision isn't priced in yet, despite the stock's move under $70. The company still burns cash with no profit, and a 17x forward sales multiple assumes durable revenue growth and payer acceptance that remain uncertain if FDA hiccups occur or reimbursement stalls. The article glosses over how fragile Galleri's cash-pay model is without broad payer coverage; a delay or denial in FDA approval could trigger multiple compression, competition from other multi-cancer tests, and slower adoption due to clinical utility questions around mortality impact. Bulls gloss over that by citing 2028 revenue targets.
However, the bullish counterpoint is that an FDA approval with broad payer coverage could unlock revenue well beyond the 2028 target if real-world uptake proves durable. The NHS data might still be repurposed to claim early-detection benefits, sustaining investor optimism despite the primary endpoint miss.
"Independent sensitivity data, if accurate, structurally limits addressable market regardless of regulatory path."
Grok's 16-20% independent sensitivity figure is the real third rail here. If true, it doesn't just delay reimbursement — it caps cash-pay uptake at wellness clinics and employer plans because physicians won't order a test that misses 4 in 5 early cancers. That undercuts every panelist's 2028 revenue ramp and makes the 17x multiple look like pure hope.
"The low clinical sensitivity of the Galleri test renders the projected revenue ramp and TAM expansion fundamentally unachievable."
Grok's sensitivity data is the fatal flaw in the bull case. If early-stage detection is truly sub-20%, the 'TAM' Claude mentions is a mirage; physicians won't order a test with such high false-negative rates, regardless of employer interest. This isn't just a regulatory delay; it’s a clinical utility crisis. We are over-analyzing the 17x sales multiple while ignoring that the core product may lack the diagnostic efficacy required to become a standard of care.
"The sensitivity figure is the crux, but it's unverified in this discussion—we need the actual study before declaring the product clinically unviable."
Grok and Gemini are conflating two separate problems: NHS trial design and Galleri's actual sensitivity. The 16-20% figure needs source verification—marketing claims vs. independent studies differ, but I haven't seen peer-reviewed data confirming sub-20% sensitivity in early-stage detection specifically. If that's accurate, it's catastrophic. But if it's misattributed or refers to stage I-only cohorts, the bull case survives. We're making a $70B valuation call on an unverified statistic. That's the real risk.
"Independent, cancer-type–specific sensitivity data is needed; blanket 16-20% early-stage sensitivity undermines the bull case unless offset by repeated testing or demonstrated mortality benefit."
Challenge Grok on the 16-20% early-stage sensitivity being the ultimate derailleur. If real-world performance is that low, the case for broad payer coverage collapses; but the NHS miss alone doesn’t seal the fate—population risk targeting, test-retest strategies, and mortality benefit in high-prevalence cancers matter. We need independent, peer‑reviewed sensitivity by cancer type and stage, not a blanket stat. Without that, 17x forward sales remains a mirage.
The panel consensus is that Grail's current valuation at 17x forward sales is overly optimistic given the uncertainty around FDA approval, Medicare coverage, and Galleri's clinical utility. The missed primary endpoint in the NHS trial and the potential low sensitivity of Galleri for early-stage cancers are significant concerns.
None identified
Low sensitivity of Galleri for early-stage cancers (16-20%)